Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

INTRODUCTION: This 28-week, phase IIIb study assessed safety and maintenance of response to certolizumab pegol (CZP) in a diverse population of rheumatoid arthritis (RA) patients, stratified by prior anti-TNF exposure, concomitant methotrexate (MTX) use and disease duration. The ability to predict a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Arthritis Res Ther
Prif Awduron: Weinblatt, Michael E., Fleischmann, Roy, van Vollenhoven, Ronald F., Emery, Paul, Huizinga, Tom WJ, Cutolo, Maurizio, van der Heijde, Désirée, Duncan, Benjamin, Davies, Owen, Luijtens, Kristel, Dougados, Maxime
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
https://ncbi.nlm.nih.gov/pubmed/26568428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0841-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg